Aileron Therapeutics Inc. (NASDAQ:ALRN) and Zafgen Inc. (NASDAQ:ZFGN) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aileron Therapeutics Inc.	N/A	0.00	31.38M	-2.13	0.00
Zafgen Inc.	N/A	0.00	59.88M	-2.04	0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides Aileron Therapeutics Inc. and Zafgen Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aileron Therapeutics Inc.	0.00%	-85%	-70%
Zafgen Inc.	0.00%	-80.1%	-58.4%

Liquidity

2.5 and 2.5 are the respective Current Ratio and a Quick Ratio of Aileron Therapeutics Inc. Its rival Zafgen Inc.’s Current and Quick Ratios are 11.8 and 11.8 respectively. Zafgen Inc. has a better chance of clearing its pay short and long-term debts than Aileron Therapeutics Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Aileron Therapeutics Inc. and Zafgen Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Aileron Therapeutics Inc.	0	0	0	0.00
Zafgen Inc.	0	0	1	3.00

Insider & Institutional Ownership

The shares of both Aileron Therapeutics Inc. and Zafgen Inc. are owned by institutional investors at 20.6% and 91.5% respectively. Insiders held 16.4% of Aileron Therapeutics Inc. shares. On the other hand, insiders held about 0.3% of Zafgen Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aileron Therapeutics Inc.	-7.83%	-2.44%	-34.85%	-62.83%	-80.2%	-81.02%
Zafgen Inc.	1.79%	-49.46%	-46.73%	-21.8%	33.25%	11.04%

For the past year Aileron Therapeutics Inc. has -81.02% weaker performance while Zafgen Inc. has 11.04% stronger performance.

Summary

Zafgen Inc. beats Aileron Therapeutics Inc. on 6 of the 7 factors.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The companyÂ’s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts.